Development of Off-the-Shelf Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cells for COVID-19 Therapeutic Intervention

Scientists produced allogeneic hematopoietic stem cell (HSC)-engineered Invariant natural killer T (iNKT) cells through TCR engineering of human cord blood CD34+ HSCs and differentiation of these HSCs into iNKT cells in an ex vivo HSC-Derived iNKT Cell Culture.